Coherus Oncology (NASDAQ: CHRS) regains Nasdaq minimum bid price compliance

Rhea-AI Filing Summary

Coherus Oncology, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing. The company previously received a Nasdaq deficiency notice on June 30, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days, giving it until December 29, 2025 to cure the issue.

On September 5, 2025, Nasdaq informed Coherus that the closing price of its common stock had been $1.00 or greater for the requisite period, restoring compliance with Listing Rule 5550(a)(2). Coherus is now in full compliance with all continued listing standards of the Nasdaq Global Market, removing the immediate risk associated with the prior deficiency notice.

Positive

• Nasdaq compliance restored: Coherus regained compliance with Nasdaq Listing Rule 5550(a)(2) after its stock maintained a closing price of at least $1.00 for the required period, removing the immediate risk from a prior minimum bid price deficiency notice.

Negative

• None.

Insights

Equity markets and listing standards analyst

Coherus has cured its Nasdaq bid-price deficiency, removing a key listing risk.

Coherus Oncology discloses that a prior Nasdaq deficiency tied to its share price has been resolved. The company had fallen out of compliance when its stock traded below $1.00 for 30 consecutive business days, triggering a formal notice on June 30, 2025 and a cure deadline of December 29, 2025 under Nasdaq’s Listing Rule 5550(a)(2).

On September 5, 2025, Nasdaq notified Coherus that its common stock had closed at or above $1.00 for the required period, restoring compliance and closing the matter. This means the shares currently meet all continued listing standards for the Nasdaq Global Market, reducing near-term delisting or transfer-to-lower-tier risk that could have affected liquidity and investor access.

While no financial figures are disclosed, the resolution of the deficiency removes an overhang related to minimum bid price rules. Future company filings will reflect whether the share price continues to satisfy Nasdaq’s standards over time.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

0001512762false00015127622025-09-052025-09-05

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 8-K

​

​

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): September 5, 2025

​

​

COHERUS ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

​

​

Delaware		001-36721		27-3615821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

333 Twin Dolphin Drive, Suite 600

Redwood City, CA 94065

(Address of principal executive offices, including Zip Code)

​

Registrant’s telephone number, including area code: (650) 649-3530

​

N/A

(Former name or former address, if changed since last report)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CHRS		The Nasdaq Global Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company  ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

​

​

​

Item 8.01. Other Events

​

As previously disclosed, on June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq. The Company had a period of 180 calendar days, or until December 29, 2025, to regain compliance with the rule referred to in this paragraph.

​

On September 5, 2025, the Company received a letter from Nasdaq notifying the Company that the Staff had determined that the closing price of the Company’s common stock was $1.00 or greater for the requisite period of time and that the Company had regained compliance with Listing Rule 5550(a)(2) and that the matter was now closed. The Company is now in full compliance with all continued listing standards of the Nasdaq Global Market.

​

​

​

​

​

​

​

​

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​	​
Date: September 8, 2025		COHERUS ONCOLOGY, INC.
​	​	​	​
​	​	By:	/s/ Dennis M. Lanfear
​	​	Name:	Dennis M. Lanfear
​	​	Title:	Chief Executive Officer

​

​

​

​

FAQ

What did Coherus Oncology (CHRS) report in this 8-K filing?

Coherus Oncology reported that Nasdaq has determined its common stock now meets the minimum bid price requirement again and that the company has regained compliance with Listing Rule 5550(a)(2), returning it to full compliance with all continued listing standards of the Nasdaq Global Market.

Why was Coherus Oncology previously out of compliance with Nasdaq rules?

On June 30, 2025, Coherus Oncology received a Nasdaq deficiency notice because its common stock had closed below $1.00 per share for 30 consecutive business days, falling short of the minimum closing bid price required for continued listing.

How did Coherus Oncology regain compliance with Nasdaq Listing Rule 5550(a)(2)?

Nasdaq informed Coherus on September 5, 2025 that the closing price of its common stock had been $1.00 or greater for the requisite period, which satisfied the minimum bid price requirement and cured the earlier deficiency.

What is the significance of Coherus being in full compliance with Nasdaq Global Market standards?

Being in full compliance with all continued listing standards of the Nasdaq Global Market means Coherus’ shares currently meet Nasdaq’s criteria to remain listed, reducing the immediate risk of delisting actions related to the prior minimum bid price deficiency.

What deadline had Nasdaq originally given Coherus to fix the bid price deficiency?

Nasdaq originally granted Coherus a 180-calendar-day period, until December 29, 2025, to regain compliance with the minimum $1.00 bid price requirement before further listing actions might be considered.

Does this 8-K discuss any other corporate events for Coherus Oncology?

This report focuses on Nasdaq’s notification that Coherus has regained compliance with the minimum bid price rule and confirms the company is now in full compliance with all continued listing standards of the Nasdaq Global Market.